Fidelity Digital Health ETF

Whales Express Bearish Sentiment on Intuitive Surgical's Options Trading

Baldwin Wealth Partners LLC MA Invests in Veeva Systems Inc. in Q3

Insulet Corporation Fixes IT Control Material Weakness

JD Health Launches Billion-Yuan Brand Alliance for Digital Upgrade of Corporate Health Consumption Market

Central Pacific Bank Trust Reduced Holdings in Insulet Corporation

Intuitive Surgical Inc. Exec Mark Brosius Sold Shares

Canaccord Genuity Group raises Insulet's target price to $450

Philips Acquires SpectraWAVE to Expand Endovascular Imaging Portfolio

GE HealthCare Signs Contract to Supply CT Scanners and MRI Systems to Indonesia

Evercore ISI Rates Insulet as Outperform with $370 Price Target

Central Pacific Bank Trust Department Sells Intuitive Surgical Stocks

Intuitive Surgical Inc.'s Senior VP Mark Brosius Sells Company Shares

GE HealthCare Technologies Obtained $750 Million Loan to Support Acquisition of Intelerad Medical Systems

Insulet Corp Director Plans to Sell 1,851 Restricted Shares

SV Capital Partners Significantly Reduces Intuitive Surgical Shares

JD Health Announces New Progress in Tumor Prevention and Treatment with Medical Large Models

Financial Giants Conduct Significant Bullish Trades in Intuitive Surgical, Citigroup Downgrades Its Rating

Wells Fargo Raises Intuitive Surgical Target Price to $654

Bayesian Capital Management Acquires Insulet Shares in Q2

Marathon Capital Management Acquires 12,054 Shares of GE HealthCare Technologies

Starfighters Space

Haoxin

Sidus Space

Mega Fortune

Jyong Biotech

Hycroft Mining

Velo3D

Tradr 2X Long QBTS Daily ETF

Creative Media & Community Trust

Tradr 2X Long FLY Daily ETF

ISRG

Health Science Stocks: Biopharma and MedTech sectors show potential. Large Cap picks include ABBV, GILD, LLY, VRTX, REGN, BMY, NVS, RHHBY. MedTech sector lagging but Intuitive Surgical (ISRG) shows promise. SMID biotechs volatile but promising. ETF trackers ARKG, IBB, XBI up significantly YTD. Expect high volatility and opportunities in late 2025 and January 2026.

Talkmarkets

Intuitive Surgical

Health Science Stocks: Recent Picks And Year End Trading… Green Screen Day Alert

DXCM

Pomerantz LLP has filed a class action lawsuit against DexCom, Inc. and certain officers, alleging violations of federal securities laws. The lawsuit claims DexCom made unauthorized design changes to its G6 and G7 devices, leading to reliability issues and increased regulatory scrutiny. Investors who acquired DexCom securities between July 26, 2024, and September 17, 2025, can join the lawsuit by December 26, 2025. The FDA issued a warning letter about manufacturing concerns, causing DexCom's stock price to drop significantly.

Acceswire

DexCom

Class Action Filing Pursued by Pomerantz LLP Against DexCom, Inc. – DXCM

DexCom Inc.'s stock rose 2.07% to $67.43, outperforming competitors on a strong trading day. The S&P 500 and Dow Jones also saw gains. DexCom's stock has risen for three consecutive days but remains 27.69% below its 52-week high. Trading volume was below average.

Dow Jones

DexCom Inc. Stock Outperforms Competitors On Strong Trading Day

DexCom Inc announced the appointment of Jacob S. Leach as President and CEO, effective January 1, 2026, following Kevin R. Sayer's resignation. Leach previously served as interim principal executive officer and will also join the board as a director. The change was disclosed in an SEC filing dated December 22, 2025.

TradingView

DexCom Inc Announces CEO Appointment

Whales have shown a bearish stance on Intuitive Surgical (NASDAQ: ISRG) with 46% of options trades being bearish. The price target for ISRG is between $400.0 to $700.0. Currently, ISRG is trading at $576.0 with a 0.62% increase. Analysts have mixed ratings with price targets ranging from $635 to $650. The anticipated earnings release is in 31 days.

benzinga_article

Spotlight on Intuitive Surgical: Analyzing the Surge in Options Activity

A class action lawsuit has been filed against DexCom Inc. for alleged securities fraud, affecting investors between January 8, 2024, and September 17, 2025. The lawsuit claims DexCom misled shareholders, causing significant stock losses. Affected investors are encouraged to join the case for compensation. The representing firm has a strong track record in securities litigation.

Reuters

DexCom Faces Class Action Lawsuit Over Alleged Securities Fraud

PODD

Insulet's stock valuation is debated among investors, with recent price at $289.62. Despite a strong run, it's up 12.8% YTD but down 12.5% over the past month. Insulet scores 1/6 on valuation checks, suggesting optimism is priced in. DCF analysis shows it's fairly valued, while PE ratio indicates overvaluation compared to industry averages. Investors weigh growth in diabetes care against competitive dynamics. Simply Wall St offers tools for narrative-based valuation analysis.

Simplywall

Insulet

Is Insulet Fairly Priced After Its Strong Run and High Earnings Multiple in 2025?

VEEV

Baldwin Wealth Partners LLC MA invested $8.61 million in Veeva Systems Inc. during the 3rd quarter, purchasing 28,887 shares. Veeva Systems, a technology company, has seen various hedge funds buying and selling its stock. The company reported strong quarterly earnings, with a net margin of 27.93% and a return on equity of 13.68%. Analysts have given Veeva Systems a 'buy' rating, with target prices ranging from $295 to $340. Insiders have sold shares worth $7.44 million in the last 90 days.

Market Beat

Veeva Systems -CL

Baldwin Wealth Partners LLC MA Invests $8.61 Million in Veeva Systems Inc. $VEEV

Veeva Systems appointed Vipin Kondath as principal accounting officer, emphasizing continuity in financial reporting. This move supports Veeva's investment narrative amid AI adoption challenges and competition. Veeva's AI product launches are crucial for future growth, with forecasts projecting $4.3 billion revenue by 2028. Analysts estimate Veeva's fair value between $230 and $312 per share, suggesting a potential 41% upside. The article provides a comprehensive analysis of Veeva's financial health and investment opportunities.

Does Veeva Systems’ (VEEV) New Accounting Leadership Deepen Its Governance and Reporting Discipline?

Pomerantz LLP has filed a class action lawsuit against DexCom, Inc. and certain officers in the Southern District of New York. The lawsuit alleges that DexCom made false and misleading statements about its G6 and G7 devices, which had unauthorized design changes causing reliability issues and health risks. The class period is from July 26, 2024, to September 17, 2025. Investors have until December 26, 2025, to seek lead plaintiff status.

Class Action Filing Initiated by Pomerantz LLP Concerning DexCom, Inc. – DXCM

Pomerantz LLP has filed a class action lawsuit against DexCom, Inc. and certain officers, alleging violations of federal securities laws. The lawsuit claims DexCom made unauthorized design changes to its G6 and G7 devices, leading to reliability issues and health risks. The FDA issued a warning letter, causing DexCom's stock price to drop. Investors have until December 26, 2025, to seek appointment as Lead Plaintiff.

Class Action Filing Announced by Pomerantz LLP Concerning DexCom, Inc. – DXCM

Insulet Corp. (PODD) shares fell 1.11% to $289.62 on Friday, underperforming compared to competitors like Eli Lilly & Co. and DexCom Inc. The stock's decline ended a two-day winning streak and it remains 18.39% below its 52-week high. Trading volume was higher than the 50-day average. The S&P 500 and Dow Jones both rose during the session.

Insulet Corp. Stock Underperforms Friday When Compared To Competitors

Intuitive Surgical Inc. (ISRG) shares rose 1.88% to $572.47, outperforming competitors Medtronic PLC and Stryker Corp. This marked the stock's third consecutive day of gains, closing 7.07% short of its 52-week high. Trading volume was significantly higher than the 50-day average.

Intuitive Surgical Inc. Stock Outperforms Competitors On Strong Trading Day

Insulet Corporation has remediated a previously disclosed material weakness in its IT controls affecting financial reporting outside North America. No reportable events or disagreements occurred with its former auditor, Grant Thornton LLP, during fiscal years 2023-2024 and up to December 15, 2025. This information was published via EDGAR by Insulet Corporation.

Insulet Discloses Remediated IT Control Weakness in Financial Reporting

Veeva Systems Inc. has filed an initial statement of beneficial ownership with the SEC, naming Vipin Kondath as the beneficial owner and Chief Accounting Officer. The filing is accessible via EDGAR, and the news brief was generated by Public Technologies using AI. This content is informational and not financial advice.

Veeva Systems Inc. Files Initial Statement of Beneficial Ownership for Chief Accounting Officer Vipin Kondath